Compare BRTX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | SNOA |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.1M |
| IPO Year | 2015 | 2006 |
| Metric | BRTX | SNOA |
|---|---|---|
| Price | $0.28 | $2.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 25.5K |
| Earning Date | 05-13-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $81,000.00 | ★ $14,288,000.00 |
| Revenue This Year | $438.78 | $23.00 |
| Revenue Next Year | $61.20 | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $0.19 | $1.77 |
| 52 Week High | $2.04 | $6.92 |
| Indicator | BRTX | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 45.82 |
| Support Level | $0.20 | $2.30 |
| Resistance Level | $0.31 | $3.85 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 54.55 | 63.79 |
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.